Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition

Authors

Samantha C. Burnham, Edith Cowan UniversityFollow
Simon M. Laws, Edith Cowan UniversityFollow
Charley A. Budgeon
Vincent Doré
Tenielle Porter, Edith Cowan UniversityFollow
Pierrick Bourgeat
Rachel F. Buckley
Kevin Murray
Kathryn A. Ellis
Berwin A. Turlach
Olivier Salvado
David Ames
Ralph N. Martins, Edith Cowan UniversityFollow
Dorene Rentz
Colin L. Masters
Christopher C. Rowe
Victor L. Villemagne
Alzheimer's Disease Neuroimaging Inititive
Australian Imaging, Biomarker & Lifestyle Research Group

Document Type

Journal Article

Publication Title

Neurobiology of Aging

ISSN

01974580

Volume

95

First Page

46

Last Page

55

PubMed ID

32750666

Publisher

Elsevier

School

Centre of Excellence for Alzheimer's Disease Research and Care / School of Medical and Health Sciences

RAS ID

32043

Comments

Burnham, S. C., Laws, S. M., Budgeon, C. A., Doré, V., Porter, T., Bourgeat, P., ... & Villemagne, V. L. (2020). Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition. Neurobiology of Aging, 95, 46-55. https://doi.org/10.1016/j.neurobiolaging.2020.06.001

Abstract

© 2020 Elsevier Inc. Neocortical Aβ-amyloid deposition, one of the hallmark pathologic features of Alzheimer's disease (AD), begins decades prior to the presence of clinical symptoms. As clinical trials move to secondary and even primary prevention, understanding the rates of neocortical Aβ-amyloid deposition and the age at which Aβ-amyloid deposition becomes abnormal is crucial for optimizing the timing of these trials. As APOE-ε4 carriage is thought to modulate the age of clinical onset, it is also important to understand the impact of APOE-ε4 carriage on the age at which the neocortical Aβ-amyloid deposition becomes abnormal. Here, we show that, for 455 participants with over 3 years of follow-up, abnormal levels of neocortical Aβ-amyloid were reached on average at age 72 (66.5–77.1). The APOE-ε4 carriers reached abnormal levels earlier at age 63 (59.6–70.3); however, noncarriers reached the threshold later at age 78 (76.1–84.4). No differences in the rates of deposition were observed between APOE-ε4 carriers and noncarriers after abnormal Aβ-amyloid levels had been reached. These results suggest that primary and secondary prevention trials, looking to recruit at the earliest stages of disease, should target APOE-ε4 carriers between the ages of 60 and 66 and noncarriers between the ages of 76 and 84.

DOI

10.1016/j.neurobiolaging.2020.06.001

Access Rights

subscription content